Milestone Pharmaceuticals (NASDAQ:MIST) Stock Moved Up to “Sell” by Wall Street Zen

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, October 12th. Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating on shares of Milestone Pharmaceuticals in a research note on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.40.

Milestone Pharmaceuticals Trading Down 20.6%

Shares of MIST stock opened at $0.52 on Friday. Milestone Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $3.06. The company has a 50 day moving average price of $0.80 and a 200 day moving average price of $1.31. The stock has a market capitalization of $64.74 million, a P/E ratio of -0.75 and a beta of 1.07. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 8.13.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $2.96 million for the quarter, compared to analysts’ expectations of $1.00 million. Equities research analysts predict that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. RVW Wealth LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth approximately $994,000. Pinnacle Wealth Planning Services Inc. purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $68,000. Valeo Financial Advisors LLC grew its position in shares of Milestone Pharmaceuticals by 12.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock valued at $127,000 after buying an additional 16,000 shares during the last quarter. HighTower Advisors LLC raised its stake in Milestone Pharmaceuticals by 100.0% during the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC raised its stake in Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock worth $455,000 after acquiring an additional 59,200 shares in the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

More Milestone Pharmaceuticals News

Here’s some of the latest news about MIST:

• Positive Sentiment: CARDAMYST product revenue reached about $1.0 million, up 73% from the prior quarter, with roughly 3,400 prescriptions and coverage across about two-thirds of commercially insured lives. CARDAMYST and runway update
• Positive Sentiment: The company plans to cut operating expenses by about 30%, while keeping its sales team and AFib-RVR Phase 3 program in place. It expects $145.4 million in cash and investments to fund operations into late 2028, beyond the trial’s anticipated second-half 2028 data readout. Company results and cost-efficiency measures
• Negative Sentiment: The CFO and CMO have left the leadership team. Although cost reductions should conserve cash, the departures and the need to scale back spending may raise concerns about execution and commercialization. Cost-cutting and leadership update

About Milestone Pharmaceuticals

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.